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Chronic Myeloid Leukemia
Introduction
Resistance to imatinib (IM) is still one of the major problems
in the treatment of chronic myeloid leukemia (CML). Several
mechanisms have been reported to cause resistance but BCR-
ABL kinase domain mutations remain the most common.1-3
Nilotinib (NI) and dasatinib (DA) are active against the majori-
ty of mutations causing IM resistance but some mutations con-
fer clinical resistance against NI (Y253H, E255K/V, F359V/C)4
or DA (V299L, T315A, F317L/I/V/C)5 or both (T315I). Hence,
mutational screening is recommended as standard of care in
patients with suboptimal response or failure either of IM or of
second-line NI or DA.6 Sanger sequencing and denaturing high-
performance liquid chromatography (D-HPLC) are considered
to be suitable techniques for identifying BCR-ABL kinase
domain mutations7 and can detect mutated clones with a sen-
sitivity of 10-25%2 and 1-10%,8 respectively. We and others
have established mutation specific techniques with higher sen-
sitivities.9-12 Some of these techniques can also provide a quan-
titative measure of the mutated clones11,12 and have been
shown to identify mutations (here referred to as ‘low-level
mutations’) overlooked by routine screening techniques.13
Low-level mutations are detectable in advanced disease states
but not during first chronic phase CML and do not affect pro-
gression-free survival of patients treated with IM.9 In contrast,
resistant mutations detected in patients after IM failure either
by Sanger sequencing or at a higher sensitivity (0.2%) by mass
spectrometry are associated with a low rate of complete cyto-
genetic responses (CCR),14 suggesting a high prognostic value
of low-level mutations detected by more sensitive techniques.
Furthermore, the number of low-level mutations at IM failure
appears to be associated with a lower rate of CCR and major
molecular response (MMR) and a higher incidence of new
resistant mutations on NI or DA second line.15 In this study, we
have further investigated the prognostic significance of low-
level mutations by studying the association between the quan-
titative level of mutated T315I BCR-ABL six months after the
start of second-line NI or DA therapy on the one hand and the
subsequent achievement of MMR at 12 months (MMR12) on
the other. Furthermore, we sought to define a quantitative cut-
off value at which low-level mutations are most informative.
Design and Methods
Patients
Two independent groups of patients were analyzed. The ‘learning’
group of 40 randomly selected CML patients was used to establish the
cut-off level of mutant T315I allele at six months that was most closely
associated with MMR12. These patients had already been studied by
our group in a comparison study of different techniques for mutation
analysis.13 To confirm the findings from the ‘learning’ group, another
40 CML patients were assigned to an independent ‘validation’ group
based on the availability of cDNA after six months on NI or DA. All
patients in both groups gave written informed consent, had previously
received between 400 and 800 mg IM/day, and were receiving second-
line NI 800 mg/day or DA 140 mg/day. The underlying clinical trials
were conducted in accordance with the Declaration of Helsinki of
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with low levels (P=0.018). Combining the groups resulted in a sensitivity and specificity of 92.9% and 87.5%,
respectively. We conclude that the quantitative level of mutant T315I allele is predictive of major molecular
response at 12 months on second-line nilotinib or dasatinib treatment.
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ABSTRACT
1975 as revised in 2000, and approved by the ethics committees of
the institutions involved. Patients’ characteristics for both groups
prior to the start of second-line tyrosine kinase inhibitor therapy
with NI or DA are given in Table 1.
Molecular analysis
Samples were analyzed by quantitative reverse-transcriptase
polymerase chain reaction (RT-PCR) for BCR-ABL, ABL and β-glu-
curonidase (GUS) and denaturing high-performance liquid chro-
matography (D-HPLC) at baseline and after three, six, nine and 12
months of treatment with NI or DA. L-PCR was performed blind-
ed after six months. RNA extraction and cDNA synthesis were
performed as previously described.16 Quantitative RT-PCR for
BCR-ABL, total ABL and GUS transcripts was performed using the
LightCyclerTM technology (Roche Diagnostics, Mannheim,
Germany).8 D-HPLC was performed on a Transgenomic WaveTM
System Model 3500 HT (Transgenomic, Omaha, NE, USA) as pre-
viously described.8 We used 10 μL of stored cDNA for L-PCR
analysis.12 The dynamic range of the L-PCR approach extends from
100% to between 0.1% to 0.05% mutant (3–3.5 log). The compar-
ative Ct method was used to calculate the percentage of T315I
mutated BCR-ABL in the positive samples with additional normal-
ization by GUS expression directly according to the equation: %
mutant allele = 2 -(ct BCR-ABLT315I – ct BCR-ABLtotal) x 100.
Statistical analysis
Of the 40 patients who were randomly selected for the learning
group, all patients with a positive T315I mutated BCR-ABL
allele/GUS level according to L-PCR were qualified for finding the
optimal cut-off level in order to identify two groups with maximal-
ly different proportions of a later MMR12. The maximum differ-
ence was identified by the cut-off level resulting in the highest
value for Fisher’s statistical test. However, to obtain a statistically
and clinical relevant result, restrictions had to be taken into
account: 1) the smaller of the two groups should contain at least
20% of the patients; 2) P value of Fisher’s test was multiplied by
the number of different T315I mutated BCR-ABL allele/GUS levels
meeting the first restriction. Thus, Bonferroni’s adjustment for the
multiple testing of all candidates for optimal cut-off level was per-
formed. In the case of a statistically significant result, the identified
cut-off level was tested in an independent validation sample. Level
of significance was 0.05. Sensitivity and specificity were calculat-
ed. The general suitability of the T315I mutated BCR-ABL allele /
GUS level for diagnosis of future MMR12 was described by a
receiver operating characteristic (ROC) curve and the area under
the curve (AUC) was calculated. All calculations were performed
with SAS software version 9.1.3 (SAS Institute, Cary, NC, USA).
Results and Discussion
The T315I mutation causes resistance to IM, NI and DA
in CML and is, therefore, an ideal model to study the prog-
nostic potential of low-level mutations, i.e. mutations
below the detection limit of Sanger sequencing and D-
HPLC. Of the initial learning group of 40 CML patients
with IM resistance, 12 achieved MMR12 on either NI (n=5)
or DA (n=7). BCR-ABL amplification of the 6-month sam-
ples (required for further L-PCR analysis) was successful in
35 patients (88%) by L-PCR; 8 of these achieved MMR12.
Eighteen of the 35 patients (52%) were positive for the
T315I mutation by L-PCR with a median of 3.71x10-4 %
(range 3.91x10-7 - 0.26%) T315I mutated BCR-ABL
allele/GUS. Of 10 patients (29%) with a quantitative level
over 10-5 BCR-ABLT315I%/GUS, none achieved MMR12 (Table
2). Three of these patients were also positive for T315I by
DPLC at six months and had BCR-ABLT315I%/GUS values by
L-PCR of 0.23 (#5), 2.6x10-5 (#15) and 0.26 (#35), respective-
ly. Compared to DHPLC, the L-PCR technique, therefore,
identified an additional 7 patients who did not achieve
MMR by 12 months.
In contrast, all 8 patients (23%) with BCR-ABLT315I%/GUS
of 10-5 or below did achieve MMR12.
Thus, the cut-off level of 10-5 BCR-ABLT315I%/GUS by L-
PCR precisely separates the T315I positive patients in the
learning group according to their subsequent achievement
of MMR12 (P<0.001) with a sensitivity and specificity of
100%.
An independent validation group of a further 40 CML
patients with IM resistance was analyzed in order to vali-
date the prognostic cut-off level previously identified in the
learning group. Nine patients achieved MMR12 on NI (n=4)
or DA (n=5). BCR-ABL amplification of the 6-month sam-
ples was successful in 40 patients by L-PCR; 6 of those
achieved MMR12. Twenty patients (50%) had mutated
T315 with a median of 7.27x10-5% (range 8.21x10-8-
1.73x10-3) mutated T315I BCR-ABL/GUS. Of these, 12
patients showed BCR-ABLT315I%/GUS over 10-5 with one of
the 12 (BCR-ABLT315I%/GUS = 3.16x10-4) achieving MMR12.
Of the 8 patients with low levels of mutated T315I (BCR-
ABLT315I%/GUS ≤10-5), 5 achieved MMR12 while 3 did not.
Thus, the cut-off level of 10-5 maintained significance in the
validation group (P=0.018). The sensitivity and specificity
to predict MMR12 in the validation group was 83.3% and
78.6%, respectively. The independent validation group,
therefore, confirmed the high sensitivity and specificity of
the chosen cut-off level (10-5 BCR-ABLT315I%/GUS) as a pre-
dictor of MMR12. Combining the results for all T315I pos-
itive patients from both groups obtained by L-PCR generat-
ed a sensitivity of 92.9% and a specificity of 87.5%.
Additional receiver operating curve (ROC) calculations con-
firmed the high association of the 6-month cut-off value
with MMR12 (AUC 0.9226). 
By D-HPLC, a T315I mutation was detected at baseline in
2 patients (#5, 22), at  three months in 3 (#5, 15, 22), at six
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median [years] 64 60
range 39-78 32-79
Phase of disease  at resistance
chronic phase 31 40
accelerated phase 7 0
myeloid blast crisis 2 0
Mutation status*
mutation 29 23




*BCR-ABL kinase domain mutation status (ABL exon 4-9) by denaturing high-perfor-
mance liquid chromatography (D-HPLC).
months in 3 (#5,15,35), at nine months in 3 (#5,15,22), and
at 12 months in 5 (#5,7,11,15,22) after second-line tyrosine
kinase inhibitor treatment (Table 3). None of the patients
who were T315I positive by D-HPLC achieved MMR12
and all had BCR-ABLT315I%GUS over 10-5 at six months by L-
PCR irrespective of the time of T315I detection by D-
HPLC, confirming close qualitative agreement between the
two methods. Once positive for T315I by D-HPLC all
patients remained positive in further samples with the
exception of #22 (6 months) and #35 (9 and 12 months). In
all 3 negative patients at six months by D-HLPC (#7, #11,
#22), L-PCR revealed a T315I level slightly below the detec-
tion limit of the D-HPLC technique. In addition to the 6
patients for whom D-HPLC detected a T315I mutation at
least once within the 12-month observation period, L-PCR
at six months identified 4 additional patients carrying T315I
mutations (#16,17,33,36) that remained undetected by D-
HPLC. Having demonstrated the biological and clinical sig-
nificance of BCR-ABL kinase domain mutations below the
detection limit of Sanger sequencing (‘low-level muta-
tions’),14,15 we have now used T315I mutated clones as an
example to establish a cut-off level of mutant allele with
prognostic significance and validated the cut-off value in an
independent group of patients. Our results have several
implications for mutation analysis in CML.
1) The level of mutated allele appears to be a valuable
indicator of whether a mutated cell clone will undergo long-
term expansion over time or not. Parker et al. used mass
spectrometry (sensitivity 0.2% mutated allele) to show a
clear association with response. In our studies, a 0.1% cut-
T. Lange et al.
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Table 3. Association of BCR-ABLT315I/GUS >10-5 (high) and BCR-ABLT315I/GUS ≤10-5 (low) by ligation-PCR with detection of the T315I mutation by
denaturing high-performance liquid chromatography (DHPLC) and achievement of MMR12. Only positive patients by DHPLC and/or L-PCR are
shown.
# D-HPLC D-HPLC D-HPLC L-PCR D-HPLC D-HPLC MMR12
resistance 3 months 6 months 6 months 9 months 12 months
2 low Yes
5 T315I T315I T315I high T315I T315I No
6 low Yes
7 high T315I No
11 high T315I No











35 T315I high No
36 high No
#: patient number, T315I: detection of BCR-ABL by denaturing high-performance liquid chromatography (DHPLC). BCR-ABL, L-PCR: ligation polymerase chain reaction for T315I
mutated BCR-ABL; GUS: β-glucuronidase expression; MMR12: major molecular response (<0.1% BCR-ABL1/ABL1 IS) after 12 months on second-line nilotinib or dasatinib.
Table 2. Prediction of major molecular response after 12 months on nilotinib or dasatinib therapy by quantification of the BCR-ABLT315I mutation.
Learning group MMR at 12 months Validation group MMR at 12 months
Patients 40 12 40 9
Evaluable results at 6 months 35 8 40 6
T315I positive by L-PCR 18 (51%) 8 20 (50%) 6
BCR-ABLT315I/GUS >10-5 10 (29%) 0 of 101 12 (30%) 1 of 122
BCR-ABLT315I/GUS ≤10-5 8 (23%) 8 of 81 8 (20%) 5 of 82
Prediction of MMR12 in T315I positive patients (n) 18 38 20
Sensitivity      100 92.9 83.3
Specificity 100 87.5 78.6 
AUC3 0.9226
1Fisher’s test: P<0.001. 2Fisher’s test: P=0.018. 3Area under the curve (AUC) was calculated by receiver operating characteristic (ROC) curves. T315I: T315I mutated BCR-ABL; L-PCR:
ligation polymerase chain reaction for T315I mutated BCR-ABL; GUS: β-glucuronidase expression; MMR12: major molecular response after 12 months on second-line nilotinib or
dasatinib.
off level corresponded best with response, although the
additional normalization with GUS led to an even better
correlation (data not shown). In conclusion, we confirm the
prognostic relevance of low-level mutations detected by
techniques with a sensitivity of 0.1-0.2% mutated allele,
although further GUS normalization is recommended if
using a quantitative technique. In this respect, it should be
noted that the complexity of the molecular techniques
involved currently limits the practical use of our findings in
the routine monitoring of CML patients.
2) Vice versa, we have demonstrated that qualitative tech-
niques with sensitivities below this cut-off level may iden-
tify additional mutated clones without prognostic conse-
quences. This may explain why Willis et al.9 found no neg-
ative impact on progression-free survival in patients for
whom low-level mutations were detected at diagnosis by
qualitative ASO-PCR with a sensitivity of at least 0.001%
mutated clone. The prognostic significance of low-level
mutations at CML diagnosis should, therefore, be re-evalu-
ated from a quantitative perspective. Mutations below our
cut-off level should only be considered clinically significant
if levels rise over time.
3) A strong association was found between patients with
T315I mutations above our cut-off level by L-PCR and T315I
mutations detected by D-HPLC. However, L-PCR identified
2 patients six months earlier than did D-HPLC and a further
4 patients with a high-level T315I mutation by L-PCR and
no MMR12, who were not identified at all by D-HPLC.
Given the evidence for poor response rates in patients with
low-level mutations,14 the ability of L-PCR to identify muta-
tions above the clinically significant cut-off level but below
the detection level of D-HPLC increases the value of muta-
tion analysis in the optimization of CML therapy. 
In summary, sensitive techniques increase the number of
patients in whom BCR-ABL mutations can be detected.
However, only mutations above a certain cut-off level seem
to be of prognostic significance. The cut-off level for the
T315I mutation lies below the detection limit of routine
screening techniques. Therefore, we recommend that rele-
vant mutations should be quantified in clinical trials to
determine mutation specific cut-off levels that have a signif-
icant influence on prognosis of the outcome of a given TKI
treatment in CML.
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